Search

Displaying results 2991 - 3000 of 5419 in total
  1. Drug

    Mupadolimab

    go.drugbank.com/drugs/DB16488
    Investigational

    NCT04464395 and NCT04734873 assessed its use for hospitalized COVID-19 patients alone or with standard care.

  2. Drug

    Estradiol dienanthate

    go.drugbank.com/drugs/DB13955
    ApprovedVet approvedWithdrawn

    Estradiol dienanthate is not currently available in any commercially available products in Canada or the US. … First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102].

  3. Drug

    Modified vaccinia ankara

    go.drugbank.com/drugs/DB15483
    ApprovedInvestigational

    Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus. Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).

  4. Drug

    INNO-305

    go.drugbank.com/drugs/DB06025
    Investigational

    INNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission.

  5. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders.

  6. Drug

    Lormetazepam

    go.drugbank.com/drugs/DB13872
    Approved

    It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.

  7. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)

  8. Drug

    Ripretinib

    go.drugbank.com/drugs/DB14840
    ApprovedInvestigational

    Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.

  9. Drug

    Human papillomavirus type 52 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10313
    ApprovedInvestigational

    (VLPs) of the major capsid (L1) protein of HPV Type 52 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs. … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles

  10. Drug

    Plasma protein fraction (human)

    go.drugbank.com/drugs/DB13968
    ApprovedInvestigational

    [A32512] It is already reviewed under the category of biologics by the FDA where the processing, required tests, requirements and labeling are incorporated.